Estimates Revisions enGene Therapeutics Inc.
Stocks
ENGN
CA29286X1015
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
08/09/2026
|
5-day change | 1st Jan Change | ||
| 1.920 USD | +5.49% |
|
+3.50% | -78.74% |
| 09-08 | EnGene Therapeutics Inc. Provides Clinical Updates | CI |
| 09-08 | EnGene Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- ENGN Stock
- Consensus enGene Therapeutics Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
